178
Last Update Posted: 2005-06-24
Recruiting has ended
All Genders accepted | 0 Years + |
Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Multicenter Trial of Prednisone in Alzheimer's Disease
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
Eligibility
Relevant conditions:
Alzheimer Disease
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov